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Abstract 
Background: Prostate stem cell antigen (PSCA) expression has been shown to correlate with prostatic carcinogen-
esis and prostate cancer (PCa) progression. The underlying mechanisms for these processes are currently unknown. 
Epithelial to mesenchymal transition (EMT) has been associated with the invasiveness and the distant metastasis of 
PCa. In this study, we investigated the effects of knocking down the PSCA on the cell migration, the invasiveness, and 
the EMT of the PCa cell line DU145 in vitro and in vivo.
Methods: Four target sequences of the small hairpin RNA for PSCA were designed, and the best effect knockdown 
sequence shRNA#1 was screened to construct the stable transfected DU145 cell line (DU145 shRNA#1), the scramble 
sequence was also designed to construct the stable transfected DU145 cell line(DU145 scramble). Cell migration and 
invasion were studied using Transwell assay. Quantitative RT-PCR, Western blot (WB) were used to quantify PSCA, 
E-cadherin, β-catenin, Vimentin, Fibronectin expression in DU145, DU145 scramble, DU145 shRNA#1 in vitro and 
in vivo. RT-PCR, immunofluorescent staining were used to quantify PSCA, E-cadherin, and Vimentin expression in vitro. 
EMT-related genes Snail, Slug, and Twist, were quantified by quantitative RT-PCR in vitro.
Results: The constructed stable knockdown of the PSCA in the DU145 cell had a silencing effect up to 90.5 %. DU145 
shRNA#1 became scattered from the tightly packed colonies. It was associated with decreased cell migration and 
invasion. There was also an increased Vimentin and Fibronectin expression, an inhibited E-cadherin and β-catenin 
expression at both the mRNA and the protein levels when compared to the DU145 and the DU145 scramble in vitro 
and vivo. Furthermore, with the exception of the Snail, the expression of EMT-related Slug and Twist genes were 
upregulated.
Conclusions: Our data indicated that knockdown of PSCA induced EMT and reduced metastatic potentials of the 
DU145 cells, suggesting that PSCA played an important role in prostatic carcinogenesis and progression.
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Background
Prostate cancer is the most commonly diagnosed cancer 
and the second leading cause of cancer-related death in 
men in the Western countries. According to the newest 
statistics, an estimated 220,800 cases of prostate cancer 
in the United States will be diagnosed. It will account for 
26 % of all newly diagnosed cancers and will result in an 
estimated 27,540 deaths in 2015 [1].
There remain significant challenges in the management of 
this disease, especially since many of the patients do even-
tually progress to metastatic disease. Androgen ablation is 
the first line treatment for the metastatic prostate cancer. 
However most of the patients will eventually become cas-
tration-resistant [2]. Currently there is no effective treat-
ment for the metastatic disease. Gene therapy seems to be a 
potential promising modality. It has been reported by many 
researchers and the effectiveness has been validated [3, 4]. 
Guo et al. [5] have postulated the possibility of developing 
a RNAi-based therapy for the prostate cancer. To do so a 
suitable treatment target would be needed.
Reiter et al. [6] evaluated many antigens in the LAPC-4 
xenograft model using representational difference analysis 
(RDA). They confirmed that the prostate stem cell antigen 
(PSCA) expression was prostate specific and it was over-
expressed in the majority of the prostate cancers. PSCA 
is located on the chromosome 8q24.2. It is composed of 
660 bp and possesses an amino-terminal signal sequence, 
a carboxyl-terminal GPI anchoring sequence, and numer-
ous N-glycosylation sites. Subsequently, many researchers 
have proven the relationship between PSCA and prostate 
cancer. Based on Reiter’s research, Gu et al. [7] found that 
as the tumor stage and the Gleason scores increased so 
was the PSCA expression. It was especially noticeable in 
the cases of bony metastases. Following Gu’s research, 
Han et  al. [8] showed that Gleason score, tumor stage, 
seminal vesicle invasion, capsular penetration, as well as 
the biochemical recurrence were all closely correlated to 
the increased PSCA expression. Lam et  al. [9] detected 
PSCA mRNA and protein expression in the clinical speci-
mens of prostate cancer. They showed that prostate cancer 
metastases, especially the bony metastases, had increased 
PSCA expression. Our group also reported that PSCA 
expression positively correlated with the increased patho-
logical grade (poor cell differentiation), heightened clini-
cal stage, and androgen-independence. We speculated 
PSCA might even have a role in the prostate carcinogen-
esis [10–12]. There was increasing evidence to show that 
PSCA was a favorable antigen for the diagnosis and treat-
ment of prostate cancer, especially for the gene therapy.
Tumor metastasis is a complicate process. The cancer cell 
has first to acquire the ability to invade into the adjacent 
organs and/or to migrate through bloodstream or lymphatic 
system to distant sites and to survive [13]. The same is true 
for the prostate cancer metastasis, especially since most of 
the prostate cancer metastasis occur in the lymph nodes 
and/or in the bones. The role of PSCA in the prostate cancer 
cell migration and invasion has yet been elucidated.
Epithelial to mesenchymal transition (EMT) in PCa 
was first proposed by Greenburg et  al. [14]. They found 
epithelial cells could transform into mesenchymal cells in 
the collagen gels. Subsequently, research on the EMT had 
gained broad interests. Currently, EMT was character-
ized by a decrease of the epithelial markers such as E-cad-
herin, an increase of the mesenchymal markers such as 
Vimentin, loss of polarity, lower adhesiveness, and higher 
mobility. EMT was considered to play a critical role in the 
tumor metastasis [15, 16]. There was ample evidence that 
EMT-like states occurred in and might contribute to the 
PCa metastasis. Therefore, it has become a very active 
area of research [17]. Ding et  al. and Gao et  al. demon-
strated that when EMT occurred in PCa cells, the cells 
would acquire mobility and invasive potential [18, 19] .
In order to elucidate the precise function of PSCA in 
the PCa and the mechanism of PSCA in the PCa metas-
tasis, we constructed a target sequence of the small hair-
pin RNA for the PSCA. Retrovirus was then used as a 
vector to create a stable transfected PCa DU145 cell line. 
We next studied the cell migration and invasion, as well 
as the epithelial-to-mesenchymal transition with the 
knockdown of PSCA in the DU145 cells.
Results
PSCA was highly expressed in the metastatic DU145 
prostate cancer cells
To investigate the role of PSCA in the PCa metastatic 
potentials, the levels of PSCA mRNA in various prostate 
cell lines were assessed. It was found that the PSCA was 
highly expressed in the DU145 metastatic PCa cells. In 
this study, DU145 cells with relative higher PSCA expres-
sion were selected to perform the experiments (Fig. 1).
Successful construction of stable knockdown of PSCA 
DU145 cell lines
The target sequence of the small hairpin RNA for the 
PSCA was designed. The sequence was then annealed 
and cloned into the psi-LVRH1GP vector. The psi-
LVRH1GP-shRNA was sequenced. The results indi-
cated that the construction of the recombined plasmid 
was successful. The best effect sequence of knockdown 
was screened, shRNA#1 was the best target knockdown 
sequence (Fig. 2). In the study, the vectors were co-trans-
fected along with the Gag/Pol, Rev, VSV-G vectors into 
the 293T cells. The retroviruses were added into DU145 
cells for the infection. The positive clones were selected 
in puromycin (5  ug/ml). The stable PSCA transfectants 
were isolated after 2 weeks of selection. The photographs 
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migration assay. To minimize the impact of the differen-
tial cell growth rates on the motility assay, we induced 
cell cycle arrest by maintaining cells under serum-
starvation conditions for 24  h before performing the 
motility assay. As shown in Fig. 6, knockdown of PSCA 
significantly reduced the cell migration of the DU145 
cells as compared to the control DU145 (P  <  0.001) 
and to the DU145 scramble (P  <  0.001). Knockdown 
of PSCA expression also remarkably reduced the num-
ber of invasive cells as compared to the control group 
(P < 0.001, for all) (Fig. 7). These consistent results sug-
gested that abolition of the expression of PSCA could 
effectively reduce the metastatic potentials of the 
DU145.
Knockdown of PSCA induced epithelial‑to‑mesenchymal 
transition in vitro
As shown in Fig. 3, DU145 shRNA#1 cells became scat-
tered from the tightly packed colonies when compared to 
the parental DU145 and the DU145 scramble cells. This 
represented one of the characteristics of EMT. To further 
determine whether PSCA induced the molecular altera-
tions of EMT in these cells, the expressions of the epithe-
lial markers E-cadherin, β-catenin and the mesenchymal 
marker Vimentin, Fibronectin were examined. QRT-PCR 
showed that the knockdown of PSCA lead to downregu-
lation of the E-cadherin, β-catenin and upregulation of 
the Vimentin, Fibronectin expression (Fig. 8a). The results 
from Western blot were consistent with those from qRT-
PCR (Fig. 8b). Immunofluorescent staining of E-cadherin 
and Vimentin showed the same results as above (Fig. 5).
Knockdown of PSCA induced EMT relating genes in DU145
One of the hallmarks of EMT is the loss of E-cadherin. 
E-cadherin transcription is silenced in many tumor and 
is considered to be a tumor suppressor. The zinc-finger 
containing the Snail and Slug proteins and the helix-
loop-helix transcription factor Twist can suppress 
the E-cadherin expression and induce EMT. To check 
whether these transcription factors were regulated by 
PSCA, the transcriptional levels of E-cadherin regula-
tors in the DU145 cells were assessed. The expression 
of the Slug and the Twist was increased but the Snail 
was downregulated in the EMT-like DU145 shRNA#1 
cells (Fig.  9). This suggested that the Snail might have 
distinct functions in the DU145 cells. These results 
indicated that PSCA regulated the EMT promoting 
genes such as the Slug and Twist, but not the Snail in 
the DU145 cells. Taken all together, these results sup-
ported the idea that the knockdown of PSCA decreased 
the migratory and invasive behavior and induced EMT 
in DU145 in vitro.
Fig. 1 PSCA is highly expressed in the metastatic DU145 prostate 
cancer cells. The expression of PSCA in various prostate cells was 
analyzed by qRT-PCR, GAPDH was used as a loading control
Fig. 2 Screened the silencing effect of the target sequence of the 
small hairpin RNA. Designed four target sequences of the small 
hairpin RNA for the PSCA, and one scrambled control, and what we 
screened the best silencing sequence was PSCA shRNA#1
of the stable knockdown of PSCA cell lines were shown 
in Fig. 3. QRT-PCR indicated that the silencing effect was 
up to 90.5 % (Fig. 4a). RT-PCR (Fig. 4b), WB (Fig. 4c), and 
immunofluorescent staining (Fig.  5) were also used to 
determine the knockdown level.   
Knockdown of PSCA reduced cell migration and invasion 
in prostate cancer DU145 cells
The effects of knockdown of PSCA on the cell motility 
of the PCa cell lines were assessed using the Transwell 
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Knockdown of PSCA induced epithelial‑to‑mesenchymal 
transition in vivo
To further explore whether knockdown of PSCA induced 
epithelial-to-mesenchymal transition in  vivo, we con-
ducted xenograft tumor model assays by subcutaneously 
injecting DU145, DU145 scramble, and DU145 shRNA#1 
cells into the right side of axillary of mice. The subcuta-
neous tumors were excised. QRT-PCR was conducted 
to confirm that DU145 shRNA#1 had the lower PSCA 
level than DU145, DU145 scramble (P  <  0.001, for all) 
(Fig.  10a). In consistent with the mRNA level, Western 
blot had the same results (Fig.  10b). Our results sug-
gested that PSCA in DU145 shRNA#1 xenograft tumor 
had also the lowest level than control (P < 0.001, for all).
In order to explore if EMT occured in vivo, we detected 
markers of EMT of E-cadherin,β-catenin, Vimentin, 
Fig. 3 The cell lines photographs of DU145, DU145 scramble, DU145 shRNA#1 DU145 white light picture (×200), DU145 scramble white light picture 
and Fluorescent images (×200), DU145 shRNA#1 white light picture and Fluorescent images (×200)
Fig. 4 Successful construction of stable knockdown of PSCA DU145 cell lines. a The mRNA level of PSCA was analyzed by QRT-PCR among DU145, 
DU145 scramble and DU145 shRNA#1. QRT-PCR indicated that the silencing PSCA level was up to 90.5 %. b The mRNA level of PSCA was analyzed 
by RT-PCR. c The protein level of PSCA was analyzed by Western blot **P < 0.001, show DU145VS DU145 shRNA#1
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Fibronectin. QRT-PCR was conducted to confirm that 
DU145 shRNA#1 had the lower level of E-cadherin, 
β-catenin than DU145, DU145 scramble (P  <  0.001, for 
all), and also had the higher level of Vimentin, Fibronec-
tin than DU145, DU145 scramble (Fig.  11a, P  <  0.001, 
for all). In consistent with the mRNA level, Western blot 
indicated the same results. (Figure 11b), which indicated 
EMT also occured in vivo.
Discussion
In this study, we designed four target sequences of a 
small hairpin RNA for PSCA and screened the best 
effect sequence for a knockdown. We then constructed 
the stable transfected DU145 cells. The silencing effect of 
the DU145 shRNA#1 attained to 90.5 % when compared 
to the control DU145. These data indicated that the 
experimental knockdown of PSCA had met our objec-
tive. We found that when knockdown of PSCA, DU145 
shRNA#1 migration to the bottom of the Transwell sig-
nificantly decreased when compared to the DU145 and 
the DU145 scramble. In addition, DU145 shRNA#1 also 
demonstrated significantly reduced invasiveness through 
the BD matrigel as compared to the DU145 and the 
DU145 scramble. These results indicated that knock-
down of PSCA decreased the metastatic potentials of 
the PCa DU145 cells in vitro. Our results was in agree-
ment with our prior study [20], in which we reported 
that silencing the PSCA using siRNA could inhibit the 
proliferative and the invasive properties of the human 
PCa cells PC3M. Combining with our prior findings, the 
conclusion that the knockdown of PSCA decreased the 
metastatic potentials of prostate cancer cells in vitro was 
reaffirmed.
In order to elucidate the mechanism affecting the 
metastatic potentials of the DU145, we investigated the 
EMT with the knock down of the expression of PSCA 
in the DU145 cell in  vitro and vivo. In this study, we 
observed the morphologic change of DU145 shRNA#1 
cells. This was characterized by the transformation from 
tightly packed colonies to scattered phenotype when 
compared to DU145 and DU145 scramble cells. Knock-
down of PSCA also downregulated the epithelial marker 
Fig. 5 Immunofluorescent staining. PSCA, E-cadherin, Vimentin was analyze by immunofluorescent staining. The results indicated that knock down 
of PSCA can decreased the expression of E-cadherin, and elevated the expression of Vimentin
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E-cadherin, β-catenin and upregulated the mesenchymal 
marker Vimentin, Fibronectin at the mRNA and protein 
level in vitro and in vivo. In addition we found that the 
EMT-related genes Slug and Twist were elevated, but the 
Snail was downregulated. Further study is needed to elu-
cidate this distinct function of the Snail in DU145 cell.
EMT was thought to promote prostate cancer metas-
tasis [21–23]. In our study, we observed that the knock-
down of PSCA decreased the metastatic potentials and 
simultaneously induced EMT in DU145. Therefore the 
decreased metastatic potential was felt to be indepen-
dently of EMT. Drake et  al. [24, 25] isolated the cell 
line TEM4-18, a subpopulation of PCa PC-3 cell line. 
They found the TEM4-18 exhibited hallmarks of EMT 
that were not in the PC-3; however, the TEM4-18 had 
a decreased migration by the Transwell assay. This was 
consistent with our findings. In the present study, in vivo 
results also showed that E-cadherin, β-catenin were 
downregulated and Vimentin, Fibronectin were upregu-
lated, suggesting an EMT. These results suggested that 
EMT might not always be associated with the changes 
of cell-autonomy that were inherent to the invasive 
behavior, or EMT had a context-dependent role in the 
metastatic cellular behavior. Further study is needed 
to confirm these findings in other prostatic cancer cell 
lines.
PSCA is a glycosylphosphatidylinositol (GPI) anchored 
cell surface antigen. It shares 30  % homology with the 
stem cell antigen 2 (SCA-2) and is also homologous to 
the Thy-1/Ly-6 family. Reiter et  al. [6] speculated that 
PSCA might play an important role in the stem/progeni-
tor cell functions such as self-renewal (anti-apoptosis). 
Bahrenberg et  al. [26] based on his finding that PSCA 
expression in RT112 cells was dependent on the cell–cell 
Fig. 6 Knockdown of PSCA decreased cell migration of DU145 cells, which were assessed by a transwell-based motility assay after migration 24 h 
(original magnifications: ×200). **P < 0.001, show DU145 VS DU145 shRNA#1
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contact and surface adhesion, drew the conclusion that 
PSCA might be related to the adhesion of the cells. Many 
authors identified that PSCA might play a role in the cell 
growth, migration, invasion in vitro, as well as the tumor 
growth and metastasis in  vivo. However, PSCA seemed 
to have diverse functions in different tumors. Ono et al. 
[27] observed PSCA could reduce cell-proliferation and 
inhibit the invasiveness of gallbladder cancer cell lines. It 
is possible that the PSCA was down-regulated in the gall-
bladder tumor since the PSCA was a tumor suppressor 
gene in gallbladder cancer. The specific mechanism was 
unclear. It deserves to be studied further.
The precise mechanisms of the PSCA regulating the 
cellular activities in cells are unknown. Marra et al. [28] 
identified that the knockdown of PSCA delayed blad-
der cancer cell growth through activating the genes 
downstream of the IFNα/β receptor. Since the PSCA is 
a GPI-anchor proteins, Saeki et al. [29] speculated that 
PSCA might work through two mechanisms. The first 
possibility was that PSCA might form compounds with 
another yet unidentified protein that controlled both 
the transmembrane and the intracellular regions. When 
PSCA bound to this protein, the resulting complex 
could activate the downstream signaling molecules. 
The second possible mechanism was that the phospho-
lipase C decomposed the GPI anchor of the PSCA. The 
PSCA would then be excreted from the membrane and 
bound with an appropriate ligand. This would start the 
next signaling cascades. How the knockdown of PSCA 
in DU145 cell regulated the cell activities in this study 
needs to be further elucidated.
A limitation of our study is that only one cell line was 
studied and the experiments were not performed using 
additional prostatic cell lines to validate the results. 
Despite this limitation, the findings presented here 
demonstrated that knockdown of PSCA could decrease 
Fig. 7 Knockdown of PSCA decreased cell invasion of DU145 cells knockdown of PSCA decreased cell invasion of DU145 cells, which were assessed 
by a transwell-based invasion assay after 24 h (original magnifications: ×200). **P < 0.001, show DU145 VS DU145 shRNA#1
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the metastasis and induce the EMT in DU145 cells. 
The decreased metastatic potential was independently 
of the EMT and the EMT was not associated with the 
metastasis of the DU145 cell line. The mechanism for the 
decrease in the metastasis with the knockdown of PSCA 
had not been revealed. Additional studies are warranted.
Conclusions
In conclusion, to our knowledge, this study is the first to 
provide evidence that knockdown of PSCA induced EMT 
and reduced metastatic potentials of the DU145 cells. It 
suggested that PSCA played an important role in pros-
tatic carcinogenesis and progression.
Methods
Cell lines and cell culture
The human prostate epithelial cell line RWPE-1, human 
PCa cell line PC3, PC3 M, DU145, and 293T were pur-
chased from Type Culture Collection of the Chinese 
Academy of Sciences (Shanghai, China). The RWPE-1 
cells were cultured in Keratinocyte Serum Free Medium 
(Gbico, Grand Island, NY, USA) and 1  % penicillin and 
streptomycin combination (KeyGEN BioTECH, Nanjing, 
China). The DU145 cells and The PC3M cells were main-
tained in RPMI1640 (Gbico) supplemented with 10  % 
fetal bovine serum (Gbico) and 1 % penicillin and strep-
tomycin combination. The PC3 cells were cultured in 
Fig. 8 Knock down of PSCA regulated the expression of EMT markers in DU145 cells. a knock down of PSCA lead to downregulation of the 
E-cadherin, β-catenin and upregulation of the Vimentin, Fibronectin expression. The expression of E-cadherin, β-catenin, Vimentin, and Fibronectin 
was detected by qRT-PCR. GAPDH was used as loading control. **P < 0.001, show DU145 VS DU145 shRNA#1. *P < 0.01, show DU145 VS DU145 
shRNA#1. b knock down of PSCA lead to downregulation of the E-cadherin, β-catenin, and upregulation of the Vimentin, Fibronectin expression. 
The expression of E-cadherin, β-catenin, Vimentin, Fibronectin was detected by Western Blot
Fig. 9 Knockdown of PSCA induced EMT relating genes in DU145 
Knock down of PSCA increased slug and twist expression, but 
decreased snail expression by qRT-PCR. *P < 0.01, show DU145 VS 
DU145 shRNA#1. #P < 0.05, show DU145 VS DU145 shRNA#1
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Ham’s F-12K (Kaighn’s) Medium (Gbico) with 10 % fetal 
bovine serum and 1 % penicillin and streptomycin com-
bination. 293T cells were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Gibco) supplemented with 
10 % fetal bovine serum and 1 % penicillin and strepto-
mycin combination. All the cells grew in standard cell 
culture conditions (5 % CO2, 95 % humidity) at 37 °C.
Antibodies and immunoblotting
Western blot analysis was conducted as previously pub-
lished by our laboratory [30]. Briefly, DU145 cells were 
collected and washed three times with phosphate-buff-
ered saline (PBS). Next each well was lysed in RIPA buffer. 
Protein concentrations were determined using the BCA 
protein assay regents (#23225, Thermo Pierce, Rockford, 
Fig. 10 PSCA expression level in xenograft tumor. a The mRNA level of PSCA was analyzed by qRT-PCR in xenograft tumor. b The protein level of 
PSCA was analyzed by Western blot in xenograft tumor. **P < 0.001, show DU145 VS DU145 shRNA#1
Fig. 11 Knock down of PSCA regulated the expression of EMT markers in DU145 xenograft tumor. a QRT-PCR was conducted to confirm the 
mRNA level of E-cadherin, β-catenin, Vimentin, and Fibronectin in DU145, DU145 scramble, DU145 shRNA#1xenograft tumor. b The protein level of 
E-cadherin, β-catenin, Vimentin, and Fibronectin was analyzed by Western blot, GAPDH was used as loading control. **P < 0.001, show DU145 VS 
DU145 shRNA#1
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IL, USA), Equal amount of protein aliquots (40–100 ug) 
were separated on a 10  % SDS polyacrylamide gel and 
transferred to a polyvinylidene difluoride (PVDF) mem-
brane (Millipore, Billerica, MA, USA). The membranes 
were blocked in 5  % non-fat dry milk in PBS-T for 
2  hours at room temperature and incubated with pri-
mary antibodies overnight at 4 °C. The primary antibod-
ies used included antibodies against PSCA (ab56338, 
1:1000 dilution, Abcam, PRC-Cambrige, UK), E-cadherin 
(cat.#1702-1, 1:1000 dilution, Epitomics, Burlingame, 
CA, USA), β-catenin (sc-7963, 1:500 dilution, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), Vimen-
tin (sc-5565, 1:500 dilution, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), Fibronectin (sc-9068, 1:500 dilu-
tion, Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
GAPDH [6C5] (ab8245, 1:3000 dilution, Abcam). The 
secondary antibodies were anti-mouse and anti-rabbit 
IgG conjugated with HRP (ab136815, ab136817, 1:3000 
dilution, Abcam), The bounded secondary antibodies 
were reacted to the ECL detection reagents (#1856135, 
Thermo) and exposed to X-ray films (#47410, Fujifilm, 
Tokyo, Japan).
Immunofluorescent staining
The cells were cultured in a 24-well plate and left to 
grow until reaching 80 % confluence. The cells were then 
washed three times with PBS for 5 min. Next they were 
fixed with 4 % paraformaldehyde for 20 min at room tem-
perature, followed by permeabilization with 0.5 % Triton 
(lot#84704, Invitrogen, Carlsbad, CA, USA). Nonspecific 
binding sites were saturated by incubation with 5 % BSA 
for 30 min at 37  °C in the cell incubator. The cells were 
incubated with PSCA, Ecadherin, or Vimentin antibody 
overnight and washed with PBS three times for 5  min. 
They were then incubated with secondary antibody 
(Alexa Fluor® 594 goat anti-rabbit IgG, Life Technolo-
gies, USA)for 1  h and washed three times with PBS for 
5 min. A drop of DAPI was added. After the DAPI was 
evenly distributed, the 24-well plate was visualized using 
an inverted microscope (ix73, Olympus, Tokyo, Japan).
Generation of the stable knockdown of PSCA cell line 
DU145
Four target sequences of the small hairpin RNA for 
human PSCA were designed (Table  1). The sequences 
were annealed and cloned into the psi-LVRH1GP vec-
tor. After successfully construction of the correct recom-
bined plasmids, the target sequence of the small hairpin 
RNA was screened for the best effect on the knockdown 
of PSCA. The best target sequence was found to be 
CCTGACCGTCATCAGCAAAGG(shRNA#1). The 
resulting vectors were then co-transfected along with 
the Gag/Pol, Rev, VSV-G vectors into the 293T cells. The 
retroviruses were added into DU145 cells for the infec-
tion. The positive clones were selected in puromycin 
(5  ug/ml). The stable PSCA transfectants were isolated 
after 2 weeks of selection.
RT‑PCR
Total RNA from DU145 cells was isolated with TRIzol 
(Invitrogen). The mRNA quality was evaluated by the 
OD260/280 ratio and only samples with a ratio of 1.8–2.0 
were used. The total RNA (1 µg) was reversely transcribed 
to the cDNA using PrimeScript® RT reagent Kit (AK2802, 
Takara, Shiga, Japan) according to the manufacturer’s 
standard operating procedure. The PCR (cat.#KT201, 
TIANGEN, Beijing, China) protocol consisted of cycling 
at 94 °C for 3 min, followed by 30 cycles of 94 °C for 30 s, 
55 °C for 30 s, and 72 °C for 60 s, and a final extension at 
72 °C for 5 min. The primers used were shown in Table 2. 
GAPDH was chosen as the internal control. The PCR 
products were electrophoresed on a 1 % agarose gel and 
the bands were visualized with ethidium bromide. Results 
were normalized with those for GAPDH.
Real‑time quantitative PCR
Using the reversely transcribed cDNA in the prior 
experiment, real-time quantitative RT-PCR was per-
formed using the SuperReal PreMix Plus (SYBR Green) 





 PSCA GCTGCTTGCCCTGTTGATGG ACATGGTCAGACTTGCGTTAG 
GA










 Vimentin TTCGCCAACTACATCGACAA 
GG
TTCAAGGTCAAGACGTGCCAG
Table 1 Designed four target sequence for the small hair-
pin RNA for the PSCA
Clone name Location PSCA target sequence
PSCA shRNA#1 229 CCTGACCGTCATCAGCAAAGG
PSCA shRNA#2 294 GCAAGAAGAACATCACGTGCT
PSCA shRNA#3 528 GAGGCACATCCTAACGCAAGT  
PSCA shRNA#4 841 GGCTGAGATGAAGTGGACTGA
Scramble GCTTCGCGCCGTAGTCTTA
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(cat.#FP205, TIANGEN). Selected sequences of the 
sense and antisense primers were used for the amplifi-
cation (Table  3). The PCR thermal cycling conditions 
consisted of an initial denaturation at 95 °C for 15 min, 
followed by 40 cycles of denaturation at 95  °C for 10 s, 
annealing at 58 °C for 20 s, and a 30 s extension at 72 °C. 
All samples were processed in triplicates and all values 
were normalized for the GAPDH expression levels. Rela-
tive quantification of mRNA levels was determined by 
ΔΔCt method.
Transwell migration assay
Cell migration was measured using sterile 6.5  mm 
Transwell® with 8.0  µm pore polycarbonate mem-
brane insert (#3422, Corning, Cambridge, MA, 
USA). 1  ×  105 DU145, DU145 scramble, and DU145 
shRNA#1 cells were loaded onto the top of a 24-well 
migration chamber in 100ul serum-free RPMI 1640 
medium. The lower chamber was filled with 0.75 ml of 
the RPMI 1640 containing 10 % FBS. After 24 h incu-
bation, cells that had migrated into the lower surface 
of the filter were fixed with 4 % paraformaldehyde and 
were stained with 0.1  % crystal violet solution. Cells 
were counted in nine random fields per insert.
Transwell invasion assay
The same sterile Transwell membrane insert was used 
to perform the invasion assay. Before commencing the 
experiment, the BD matrigel (#356234, BD Biosciences, 
Franklin Lakes, NJ, USA) was placed in a −4  °C refrig-
erator for 24 h. The BD matrigel would turn into liquid. It 
was diluted to 1:9 ratios with RPMI 1640. The bottom of 
the Transwell upper chamber was filled with 50 ul of the 
diluent. The Transwell insert was incubated for 3 h until 
the matrigel clotted. The similar steps were performed 
as the migration assay: 1 × 105 DU145 cells were loaded 
into the upper chamber of a 24-well matrigel invasion 
assay plate, the lower chamber was filled with 0.75 ml of 
RPMI 1640 medium containing 10 % FBS. After 24 h of 
incubation, cells that had migrated to the lower surface 
of the filter were fixed with 4  % paraformaldehyde and 
stained with 0.1 % crystal violet solution. Cell count was 
performed in nine random fields per insert.
In vivo study
Fifteen 6-week-old male BALB/c nude mice were sup-
plied by the Experimental Animal Center of Guangdong 
province, China. All experimental animal protocols were 
approved by the Animal Care and Use Ethics Committee. 
The animals were maintained in a special pathogen free 
facility. All the mice were randomly divided into three 
groups of five mice each. DU145 cells were collected, 
washed, and resuspended in serum-free medium at a 
concentration of 5 × 107 cells/ml. Aliquots of 100 ul cells 
from each group were subcutaneously injected into the 
right side of axillary region of each animal. The animals 
were followed for 4 weeks, the mice were sacrificed, and 
the tumors were dissected and put them into liquid nitro-
gen container for Quantitative RT-PCR and Western blot.
Statistical analysis
All of the experiments were performed in triplicates. 
Data were presented as the mean ± SD. The differences 
between groups were analyzed using one-way analysis 
of variance. All the statistical analyses were performed 
using the SPSS 18.0 software. P < 0.05 were considered to 
be statistically significant.
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